Schizophrenia Clinical Trial
— CANGLIAOfficial title:
Endocannabinoid Control of Microglia Activation as a New Therapeutic Target in the Treatment of Schizophrenia
Verified date | March 2020 |
Source | UMC Utrecht |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of this study is to compare microglia activation as measured with proton Magnetic Resonance Spectroscopy (1H-MRS) between recent-onset schizophrenia patients who are randomised to CBD and those randomised to placebo.
Status | Completed |
Enrollment | 32 |
Est. completion date | January 31, 2020 |
Est. primary completion date | January 31, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 40 Years |
Eligibility |
Inclusion Criteria: - A DSM-IV diagnosis of 295.x (schizophrenia, schizophreniform disorder or schizoaffective disorder) or 298.9 (psychosis NOS). Diagnosis must be confirmed in writing by the treating psychiatrist. - Age 16 - 40 - Onset of first psychosis no longer than five years ago - Written informed consent of the subject Exclusion Criteria: - Any clinically significant medical condition that may influence the results of the trial or affect the ability to take part in a trial - Routine laboratory screening values considered an impediment for participation by a medical doctor (see Appendix 1) - Positive urine test on any drug of abuse, except cannabis - Treatment with more than one antipsychotic agent or with an unstable dose of one type of antipsychotic medication in the month prior to study inclusion - Use of glucocorticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) within two weeks prior to study inclusion - Use of co-medication other than antipsychotics that has a clinically relevant interaction with the cytochrome P450 (CYP) 2C19 or CYP3A classes of liver enzymes within two weeks prior to study inclusion (because CBD may be an inhibitor of these classes of liver enzymes; see paragraph 6.3) - Intake of investigational drug within one month prior to study inclusion - Daily use of alcohol or drugs of abuse (including cannabis) in the three months prior to study inclusion - Any current or previous neurological disorder, including epilepsy - History of head injury resulting in unconsciousness lasting at least 1 hour - IQ < 70, as measured with Dutch version of the National Adult Reading Test (DART) - Breastfeeding, pregnancy or attempting to conceive - MRI contraindications, e.g. claustrophobia or metal objects in or around the body |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Utrecht | Utrecht |
Lead Sponsor | Collaborator |
---|---|
UMC Utrecht |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | the concentration of prefrontal metabolites as measured with 1H-MRS | the concentration of prefrontal metabolites as measured with 1H-MRS, with the level of myo-inositol being regarded as a marker of glia function | 4 weeks | |
Secondary | Tolerability associated with CBD treatment | Number of treatment-related adverse events as assessed by the study physician | 4 weeks | |
Secondary | Psychotic symptoms | Measured with the Positive and Negative Syndrome Scale (PANSS) | 4 weeks | |
Secondary | Depressive symptoms | Measured with the Hamilton Depression Rating Scale (HAM-D) | 4 weeks | |
Secondary | Anxiety | Measured with the State-Trait Anxiety Inventory (STAI) | 4 weeks | |
Secondary | Clinical impression | Measured with the Clinical Global Impressions Scale (CGI) | 4 weeks | |
Secondary | Psychosocial functioning | Measured with the Global Assessment of Functioning scale (GAF) | 4 weeks | |
Secondary | Social and Occupational functioning | Measured with the Social and Occupational Functional Assessment Scale (SOFAS) | 4 weeks | |
Secondary | Role functioning | Measured with the Global Functioning Role (GF:R) scale | 4 weeks | |
Secondary | Social functioning | Measured with the Global Functioning Social (GF:S) scale | 4 weeks | |
Secondary | Cognitive function | Measured with the Brief Assessment of Cognition in Schizophrenia (BACS) | 4 weeks | |
Secondary | CBD plasma concentrations | 4 weeks | ||
Secondary | Blood cytokine concentrations | Examples of cytokines that could be assessed in the current study include but are not restricted to interferon-?, interleukin (IL)-1a, IL-1RA, IL-6, IL-10, IL-12, IL-15, tumour necrosis factor-a, and S100B | 4 weeks | |
Secondary | Haematological blood parameters | Platelet activation and platelet aggregate formation are measured | 4 weeks | |
Secondary | MRI measures | Brain structure and function | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |